Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study

Jaroslaw B. Cwikla, MD, PhD, Professor UWM132 enrolled

Overview

This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern centres in Poland. The group of patients consists of 47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period ranged from 0 to 192 months. For all patients included to the analysis, the clinical stage was estimated according to TNM Classification of Malignant Tumours - UICC from 2017. The degree of pathomorphic stage (pTNM) was assessed in 60 patients treated with intention to treat (ITT), which is 45% of the total population. The degree of clinical stage (cTNM) was assessed in 72 patients based on the imaging examinations (including PET, CT, MRI, bone scintigraphy, etc.) and fine needle aspiration biopsy (FNA) (including EBUS, with pathological confirmation of LCNEC, which is 55% of the total population. The clinical stage (cTNM) was used in case of patients disqualified from radical surgery due to: advanced disease, contraindications to surgery, no patient's consent for treatment.

Study Type

OBSERVATIONAL

Enrollment

132

Conditions

Survival Outcomes of Patients With Pulmonary LCNEC

Eligibility

Sex: ALLMin age: 18 YearsMax age: 86 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults ≥18 years old, male or female, with pathologically confirmed primary neuroendocrine lung cancer based on histopathological examination: 1. LCNEC 2. combined type LCNEC * Patients with LCNEC, combined LCNEC without prior treatment independently from the clinical stage according to the 8th edition of TNM 2017 * Patients with generalized, unresectable of LCNEC, combined LCNEC before, during and after palliative treatment * Patients with generalized, unresectable LCNEC, combined LCNEC treated only symptomatically * Patients with locally advanced, unresectable LCNEC,combined LCNEC before, during and after radical treatment * Patients with locally advanced, resectable LCNEC, combined LCNEC before, during and after treatment Exclusion Criteria: * NA

Outcomes

Primary Outcomes

PFS - Progression Free Survival

the time from the start of treatment date to the date of first observation of documented local recurrence, metastases or disease progression. Patients without progression at the time of analysis will be censored.

Time frame: 16 years

OS - Overall Survival

is defined as the time from the histopathological confirmation to the date of death due to any cause or the date of last contact (censored observation) at the date of data cut-off.

Time frame: 16 years

Secondary Outcomes

Log-rank test

assessment of differences in survival of patients between subgroups

Time frame: 16 years

Cox proportional-hazards model

multivariate analyses used for investigating the association between the survival time of patients and prognostic factors

Time frame: 16 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.